(perindopril erbumine) Tablets
ACEON® (perindopril erbumine) Tablets is the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
ACEON® (perindopril erbumine) Tablets is indicated for the treatment of patients with essential hypertension. ACEON® Tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics.
When using ACEON® Tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether ACEON® Tablets has a similar potential. (See WARNINGS.)
In considering use of ACEON® Tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS:
Head and Neck Angioedema .)
Published Studies Related to Aceon (Perindopril Erbumine)
Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteers. 
The present study was performed to compare the bioavailability of two perindopril erbumine (CAS 107133-36-8) 4 mg tablet formulations (test formulation and reference formulation). This study was a randomized, single-blind, two-period, two-sequence cross-over study which included 20 healthy adult male and female subjects under fasting conditions...
Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. [2010.12]
CONCLUSION: The treatment benefits of a routine administration of a fixed combination of perindopril-indapamide to patients with type 2 diabetes on cardiovascular and renal outcomes, and death, are consistent across all stages of CKD at baseline. Absolute risk reductions are larger in patients with CKD highlighting the importance of blood pressure-lowering in this population.
Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis. [2010.09.20]
OBJECTIVE: To determine the cost-effectiveness of routine administration, irrespective of blood pressure (BP), of a fixed-dose combination of perindopril and indapamide to patients with type 2 diabetes mellitus... CONCLUSION: The combination of perindopril and indapamide in patients with type 2 diabetes appears to be cost-effective. TRIAL REGISTRATION: United States National Library of Medicine NCT00145925.
The effect of treatment based on a diuretic (indapamide) +/- ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). [2010.09]
BACKGROUND: fractures may have serious implications in an elderly individual, and fracture prevention may include a careful choice of medications. DESIGN: the Hypertension in the Very Elderly Trial (HYVET) was a double-blind placebo-controlled trial of a thiazide-like diuretic (indapamide 1.5 mg SR) with the optional addition of the angiotensin-converting enzyme (ACE) inhibitor (perindopril 2-4 mg). Fracture was a secondary end point of the trial. SETTING: HYVET recruited participants from Eastern and Western Europe, China, Australasia, and Tunisia. SUBJECTS: all participants were > or =80 years of age and hypertensive... CONCLUSIONS: despite the lowering of blood pressure, treatment with a thiazide-like diuretic and an ACE inhibitor does not increase and may decrease fracture rate.
The angiotensin-converting enzyme inhibitor perindopril treatment alters cardiovascular and subjective effects of methamphetamine in humans. [2010.08.30]
A variety of medications have been assessed for their potential efficacy for the treatment of methamphetamine dependence... There were significant perindoprilmethamphetamine interactions for diastolic blood pressure and for ratings of "Any Drug Effect", indicating inverted U dose-effect functions for these indices.
Clinical Trials Related to Aceon (Perindopril Erbumine)
Comparison of SevikarŪ and the Combination of Perindopril/Amlodipine on Central Blood Pressure [Recruiting]
Comparison of the combination of amlodipine with an angiotensin receptor blocker or an
angiotensin converting inhibitor, on central arterial blood pressure in patients with
hypertension and additional risk factors. This is a randomised, double-blind, double-dummy,
multicenter study. The duration of active treatment 24 weeks.
Study to Determine the Efficacy of Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension [Not yet recruiting]
The purpose of this 7- to 13-month study is to determine the efficacy of 8 mg/day oral
perindopril to prevent the recurrence of atrial fibrillation (AF) in patients with essential
Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study [Not yet recruiting]
This study is looking to evaluate which drug combination, olmesartan/amlodipine or
perindopril/amlodipine, is better at lowering blood pressure in people with mild to moderate
hypertension. We will be enrolling people who are either currently taking medication to
lower their blood pressure or who have been recently diagnosed with high blood pressure and
are not yet on medication.
Patients on medication for their blood pressure will be asked to stop taking this medication
for 2 to 4 weeks. If their blood pressure is suitable (not too high or low) they will be
randomised to one of their treatment arm:
Group 1 will receive Perindopril on its own (5mg for 4 weeks followed by 10mg for 8 weeks).
There will be 80 patients in this group.
Group 2 will receive Perindopril and Amlodipine together (5mg/5mg for 4 weeks, 10mg/5mg for
a further 4 weeks then 10mg/10mg for the final 4 weeks). There will be 80 patient in this
Group 3 will receive Olmesartan and Amlodipine together (20mg/5mg for 4 weeks, 40mg/5mg for
a further 4 weeks then 40mg/10mg for the final 4 weeks). There will be 120 patients in this
During the study we will measure the patients blood pressure and heart rate, weight and
perform routine blood tests. They will also have ECGs (3 occasions) and 24 hour blood
pressure monitor (4 occasions).
At the end of the study patients pre-study medication will be restarted or they will be put
on to a suitable alternative.
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease [Recruiting]
The aim of this current study was to assess the therapeutic effects of perindopril and
telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic
effects of these two kind of drugs.
This study is a randomized parallel control clinical trial which would be carried out in
Nanfang Hospital, Southern Medical University.
About one hundred and eighty patients would be randomly assigned to perindopril,telmisartan
and amlodipine three groups.
Cardiovascular Response and Adverse Events Associated With Perindopril in Treating Methamphetamine Dependent Individuals - 1 [Recruiting]
Due to its ease of synthesis and powerful psychostimulant effects, abuse of methamphetamine
has increased rapidly over the last decade. No medications are currently approved for the
treatment of methamphetamine dependence or withdrawal. The purpose of this study is to
determine whether perindopril, an angiotensin converting enzyme (ACE) inhibitor, modifies
cardiovascular responses and adverse events when taking methamphetamines.
Reports of Suspected Aceon (Perindopril Erbumine) Side Effects
Drug Ineffective (17),
Blood Pressure Increased (12),
Drug Interaction (9),
Renal Failure Acute (9),
Cough (8), more >>